Daily Stock Analysis, ADAP, Adaptimmune Therapeutics PLC, priceseries

Adaptimmune Therapeutics PLC. Daily Stock Analysis
Stock Information
Open
8.54
Close
8.62
High
8.79
Low
8.33
Previous Close
8.51
Daily Price Gain
0.11
YTD High
9.71
YTD High Date
Jan 26, 2018
YTD Low
6.66
YTD Low Date
Jan 2, 2018
YTD Price Change
1.52
YTD Gain
21.41%
52 Week High
9.71
52 Week High Date
Jan 26, 2018
52 Week Low
3.88
52 Week Low Date
Feb 23, 2017
52 Week Price Change
4.51
52 Week Gain
109.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 2. 2018
7.10
Jan 16. 2018
7.48
9 Trading Days
5.36%
Link
Company Information
Stock Symbol
ADAP
Exchange
NasdaqGS
Company URL
http://www.adaptimmune.com
Company Phone
44 1235 430000
CEO
James Julian Noble
Headquarters
-
Business Address
101 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RY
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001621227
About

Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.